The number of shares and votes in BICO Group AB (publ) (“BICO”) have increased following the exercise of 32,000 warrants pursuant to BICO’s warrant programme 2018 for subscription of 32,000 shares of series B.

As of September 30, 2021, the total number of registered and outstanding shares of BICO amounts to 57,707,417, of which 1,500,000 are shares of series A and 56,207,417 are shares of series B, corresponding to a total of 71,207,417 votes. The share capital amounts to SEK 1,442,685.425. The company does not hold any treasury shares.

For further information, please contact:

Gusten Danielsson, CFO                            
Phone (US): +1 (857) 332 2138

Phone (Sweden): +46 709 91 86 04     
Isabelle Ljunggren, Head of Communications                            
Phone (Sweden): +46 708 30 08 90


This is information that BICO Group AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on September 30, 2021, 08:00 a.m. (CEST).

About BICO

Founded in 2016, BICO (formerly CELLINK) is the leading Bio Convergence company in the world by combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health. The Group’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,000 publications. BICO is listed on Nasdaq Stockholm under BICO.